Evidence analysisOctober 29, 2026Health & Science

Immunogenicity and safety of Institut Pasteur du Cambodge (IPC) and updated Thai Red Cross (UTRC) intradermal rabies vaccine regimens among healthy adults in India: A phase 4, open label, equivalence randomised controlled trial

FreedomWitness Evidence Engine: This is an AI-assisted original analysis built from the linked source and available public source context. It separates evidence from interpretation and may challenge conventional framing only where the evidence supports it. It is not a copied article.

Immunogenicity and Safety of Shorter Intradermal Rabies Vaccine Regimens in India: Evidence from a Phase 4 Trial

Rabies remains a fatal viral disease with significant public health impact worldwide, especially in India, which bears a large proportion of the global burden. Post-exposure prophylaxis (PEP) through anti-rabies vaccination is critical for preventing rabies after exposure, such as dog bites. However, compliance with vaccination schedules can be challenging, particularly when regimens require multiple visits over extended periods. A recent phase 4 randomized controlled trial published in PLOS Medicine examines the immunogenicity and safety of a shorter 1-week intradermal regimen developed by the Institut Pasteur du Cambodge (IPC) compared to the longer 1-month Updated Thai Red Cross (UTRC) regimen, using two vaccine types widely used in India.

What is established

  • Rabies causes approximately 59,000 deaths globally each year, with India accounting for about one-third of the deaths.
  • Post-exposure prophylaxis involving rabies vaccination is effective in preventing rabies if administered correctly and fully.
  • Commonly used rabies vaccines in India include the Purified Chick Embryo Cell vaccine (PCECV) and the Purified Vero Cell Rabies vaccine (PVRV).
  • The conventional Updated Thai Red Cross (UTRC) regimen comprises four intradermal vaccine sessions over one month and is known to be effective but involves multiple clinic visits.
  • Shorter vaccination regimens could enhance compliance and accessibility by reducing the number of doses and visits needed.

What the source claims

The randomized controlled phase 4 trial conducted between October and December 2023 enrolled 400 healthy adult volunteers in India. Participants were randomly assigned to receive either the 3-session, 1-week IPC regimen or the 4-session, 1-month UTRC regimen with either PCECV or PVRV vaccines. The primary outcome measured was rabies virus neutralizing antibody (RVNA) titres at day 42 post-vaccination, with equivalence defined within a specific statistical margin.

Key findings include:

  • The IPC regimen did not meet the prespecified criterion for equivalence compared to UTRC in terms of geometric mean concentrations of RVNA at day 42; IPC produced lower antibody levels for both vaccines.
  • Despite lower antibody levels, all participants in all groups achieved RVNA titres indicative of seroprotection (≥0.5 IU/mL) from day 14 up to one year.
  • Adverse events reported were mostly mild and similar between regimens and vaccine types.
  • Approximately a quarter of participants had measurable RVNA titres before vaccination despite exclusion criteria, suggesting prior unrecognized immune priming.

The authors note the limitations of conducting the trial on healthy volunteers rather than individuals exposed to rabies, which may affect applicability of findings to routine PEP settings.

What may be missing from the usual framing

The study focuses on immunogenicity and safety of shortened PEP regimens in a controlled environment, but does not fully address how these findings translate into real-world effectiveness after animal bites, especially in high-risk or immunocompromised populations. The nearly 25% baseline seropositivity among participants, despite screening, may confound interpretation of immune responses; this indicates a background level of prior exposure or vaccination that is not well accounted for in the analysis. Furthermore, the study does not report on cost-effectiveness analyses or broader health system factors, such as vaccine availability and patient adherence challenges, which are critical in policy decisions.

Competing evidence or uncertainty

  • The IPC regimen’s non-equivalence in antibody levels compared to UTRC contrasts with observational studies from Cambodia suggesting the shorter regimen is effective, highlighting potential geographic or demographic variability.
  • The unknown clinical significance of lower antibody levels despite adequate seroprotection titres introduces a degree of uncertainty about long-term protection and effectiveness in high-risk groups.
  • Compliance and completion rates in actual PEP following animal bites may differ significantly from trial participants, affecting vaccine performance and effectiveness.
  • Limited data exist comparing these regimens specifically in children, immunocompromised patients, or diverse settings within India.

Why it matters

Rabies remains a deadly yet preventable disease, and optimizing PEP regimens for better compliance without compromising safety or protection is crucial for reducing mortality. Shorter regimens like the IPC protocol offer the promise of fewer clinic visits and improved patient adherence, especially in resource-constrained settings. However, evidence that abbreviated regimens might yield lower antibody levels questions if they can reliably replace longer protocols without increased risk. Policy makers and public health authorities must weigh immunogenicity data together with programmatic feasibility, cost, patient behavior, and local epidemiology in deciding on rabies PEP guidelines.

What to verify next

  • Real-world effectiveness of the IPC 1-week regimen in patients with confirmed rabies exposures, including varied wound categories and populations.
  • Long-term durability of vaccine-induced protection beyond one year, especially comparing immunogenicity and clinical endpoints.
  • Impact of baseline RVNA seropositivity on response to PEP vaccination and its implications for interpreting immunogenicity studies.
  • Cost-benefit analyses incorporating patient compliance, vaccine costs, and health system constraints for different regimens in India and similar settings.
  • Safety and immunogenicity in vulnerable groups such as children, elderly, and those with immunosuppression.

Readers are encouraged to consult the original PLOS Medicine publication for detailed methodology, data, and discussion to form a comprehensive understanding of the trial findings and their potential implications. This evidence contributes to the ongoing evaluation of rabies PEP strategies, where optimizing protection must be balanced with practical considerations of vaccine delivery and patient adherence.

Source & verification

Primary source: PLOS Medicine · October 29, 2026

Read the original source

FreedomWitness links to the original source so readers can inspect the underlying material and judge the context for themselves.

Continue reading

EudraGMDP database

What is established The EudraGMDP database is an established European Union (EU) information system managed by the European Medicines Agency (EMA). It serves as…